ECSP13012431A - Combinación del compuesto glyt1 con antipsicóticos - Google Patents

Combinación del compuesto glyt1 con antipsicóticos

Info

Publication number
ECSP13012431A
ECSP13012431A ECSP13012431A ECSP13012431A EC SP13012431 A ECSP13012431 A EC SP13012431A EC SP13012431 A ECSP13012431 A EC SP13012431A EC SP13012431 A ECSP13012431 A EC SP13012431A
Authority
EC
Ecuador
Prior art keywords
glyt1
combination
antipsychotics
compound
schizophrenia
Prior art date
Application number
Other languages
English (en)
Inventor
Jean-Luc Moreau
Joseph G Wettstein
Daniela Alberati
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44512856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012431(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP13012431A publication Critical patent/ECSP13012431A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una combinación farmacéutica de un inhibidor del transportador de glicina (GlyT1) y un fármaco antipsicótico atípico que puede utilizarse para el tratamiento de los síntomas positivos y negativos de la esquizofrenia.
ECSP13012431 2010-08-09 2013-02-07 Combinación del compuesto glyt1 con antipsicóticos ECSP13012431A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10172316 2010-08-09

Publications (1)

Publication Number Publication Date
ECSP13012431A true ECSP13012431A (es) 2013-03-28

Family

ID=44512856

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012431 ECSP13012431A (es) 2010-08-09 2013-02-07 Combinación del compuesto glyt1 con antipsicóticos

Country Status (29)

Country Link
US (1) US20120035156A1 (es)
EP (1) EP2603219B1 (es)
JP (1) JP2013533297A (es)
KR (1) KR101455947B1 (es)
CN (1) CN103068388A (es)
AR (1) AR084401A1 (es)
AU (1) AU2011288536B2 (es)
BR (1) BR112013003068A2 (es)
CA (1) CA2803656A1 (es)
CL (1) CL2013000378A1 (es)
CR (1) CR20130027A (es)
CY (1) CY1115886T1 (es)
DK (1) DK2603219T3 (es)
EA (1) EA201291477A1 (es)
EC (1) ECSP13012431A (es)
ES (1) ES2521596T3 (es)
HR (1) HRP20141199T1 (es)
MA (1) MA34457B1 (es)
MX (1) MX2013001166A (es)
NZ (1) NZ604891A (es)
PE (1) PE20131100A1 (es)
PH (1) PH12013500078A1 (es)
PL (1) PL2603219T3 (es)
PT (1) PT2603219E (es)
SG (1) SG187108A1 (es)
SI (1) SI2603219T1 (es)
TW (1) TW201211019A (es)
WO (1) WO2012019970A1 (es)
ZA (1) ZA201300434B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI2753632T3 (fi) 2011-09-08 2023-08-02 Sage Therapeutics Inc Neuroaktiivisia steroideja, koostumuksia ja niiden käyttöjä
RS67266B1 (sr) 2013-03-13 2025-10-31 Sage Therapeutics Inc Neuroaktivni steroidi i postupci za njihovu upotrebu
WO2015082367A1 (en) * 2013-12-03 2015-06-11 F. Hoffmann-La Roche Ag Pharmaceutical composition
CA2946153C (en) * 2014-04-30 2022-06-14 Yufeng Jane Tseng Use of known compounds as d-amino acid oxidase inhibitors
ES2970222T3 (es) 2014-06-18 2024-05-27 Sage Therapeutics Inc Oxiesteroles y procedimientos de uso de los mismos
EP3204011A4 (en) * 2014-10-07 2018-06-20 Sage Therapeutics, Inc. Neuroactive compounds and methods of use thereof
MA42409A (fr) 2015-07-06 2018-05-16 Sage Therapeutics Inc Oxystérols et leurs procédés d'utilisation
FI3828194T3 (fi) 2015-07-06 2025-07-17 Sage Therapeutics Inc Oxysteroleita ja menetelmiä niiden käyttämiseksi
MX390271B (es) 2015-07-06 2025-03-20 Sage Therapeutics Inc Oxiesteroles y metodos de uso de los mismos
US20190330259A1 (en) 2016-04-01 2019-10-31 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
LT3481846T (lt) 2016-07-07 2021-08-25 Sage Therapeutics, Inc. 11-pakeistieji 24-hidroksisteroliai, skirti naudoti gydant su nmda susijusias būkles
JP7149266B2 (ja) 2016-09-30 2022-10-06 セージ セラピューティクス， インコーポレイテッド Ｃ７置換オキシステロールおよびｎｍｄａモジュレーターとしての方法
IL293231B2 (en) 2016-10-18 2025-10-01 Sage Therapeutics Inc Oxysterols and methods of use thereof
MA46566A (fr) 2016-10-18 2019-08-28 Sage Therapeutics Inc Oxystérols et leurs procédés d'utilisation
CN107469087A (zh) * 2017-09-10 2017-12-15 孙永丽 用于治疗精神病的制剂
WO2019098634A1 (ko) * 2017-11-14 2019-05-23 에스케이바이오팜 주식회사 카바메이트 화합물을 포함하는 조현병의 예방, 경감 또는 치료용 배합물
EP4087570A4 (en) 2020-01-09 2024-04-03 Disc Medicine, Inc. METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA85194C2 (ru) * 2003-08-11 2009-01-12 Ф.Хоффманн-Ля Рош Аг Пиперазины с or-замещенной фенильной группой и их применение как ингибиторов glyt 1
WO2006000222A2 (en) * 2004-06-24 2006-01-05 H. Lundbeck A/S The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia
KR100969402B1 (ko) * 2005-04-08 2010-07-14 화이자 프로덕츠 인크. Ｉ형 글리신 수송 억제제로서의 비시클릭 [3.1.0]헤테로아릴 아미드
GB0612420D0 (en) * 2006-06-22 2006-08-02 Glaxo Group Ltd Compounds
UA94615C2 (uk) * 2006-06-28 2011-05-25 Амген Інк. Інгібітори транспортера-1 гліцину

Also Published As

Publication number Publication date
CN103068388A (zh) 2013-04-24
CA2803656A1 (en) 2012-02-16
HRP20141199T1 (hr) 2015-02-13
ZA201300434B (en) 2013-09-25
AR084401A1 (es) 2013-05-15
EP2603219A1 (en) 2013-06-19
CY1115886T1 (el) 2017-01-25
SG187108A1 (en) 2013-02-28
EP2603219B1 (en) 2014-09-17
CL2013000378A1 (es) 2013-05-03
MA34457B1 (fr) 2013-08-01
TW201211019A (en) 2012-03-16
EA201291477A1 (ru) 2013-06-28
PH12013500078A1 (en) 2013-03-11
PL2603219T3 (pl) 2015-03-31
PT2603219E (pt) 2014-11-25
DK2603219T3 (da) 2014-10-13
CR20130027A (es) 2013-03-04
KR101455947B1 (ko) 2014-10-28
PE20131100A1 (es) 2013-09-23
KR20130045379A (ko) 2013-05-03
ES2521596T3 (es) 2014-11-13
WO2012019970A1 (en) 2012-02-16
NZ604891A (en) 2015-01-30
BR112013003068A2 (pt) 2016-06-28
AU2011288536A1 (en) 2013-01-31
SI2603219T1 (sl) 2014-12-31
AU2011288536B2 (en) 2014-10-09
JP2013533297A (ja) 2013-08-22
MX2013001166A (es) 2013-03-22
US20120035156A1 (en) 2012-02-09

Similar Documents

Publication Publication Date Title
CR20130027A (es) COMBINACIÓN DEL COMPUESTO GlyT1 CON ANTIPSICÓTICOS
MX2019009853A (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
MX391175B (es) Macrociclos peptidomimeticos.
CU24397B1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b
ECSP13013074A (es) Nuevos derivados de piridina
GT201200144A (es) Composición farmacéutica que comprende un agonista de glp-1, una insulina y metionina
MX336741B (es) Composiciones farmaceuticas de moduladores de c-met.
CO6430459A2 (es) Derivados de prolina como inhibidores de catepsina
GT201200230A (es) Inhibidores del virus de la hepatitis c
CR20150447A (es) Nuevos derivados de pirazol
CR20150250A (es) Nuevos derivados de piridina
ECSP13012414A (es) Combinaciones que comprenden antipsicóticos atípicos y agonistas taar1
CL2012001911A1 (es) Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa.
CR20150277A (es) Piridina-2-amidas utiles como agonistas cb2
EA201590807A1 (ru) Стабильные бесконсервантные мидриатические и противовоспалительные растворы для инъекций
PE20142182A1 (es) Inhibidores de iap
BR112013028512A2 (pt) cápsula
CR20150204A (es) Nuevos derivados de piridina
CR20150440A (es) Nuevos derivados de piridina
CR20150210A (es) Nuevos derivados de pirazina como agonistas receptores de cb2
CR20150511A (es) Nuevos derivados de purina
BR112014016803A2 (pt) amidas macrocíclicas como inibidoras de protease
BR112014012521A2 (pt) novos derivados de pirrolidina como inibidores de catepsina
CU24326B1 (es) COMPOSICIÓN FARMACÉUTICA QUE INCLUYE UN INHIBIDOR DE LA HMG-Coa REDUCTASA QUE MINIMIZA LA INTERACCIÓN DEL ÁCIDO ACETILSALICÍLICO CON LA ESTATINA
CL2015000610A1 (es) Derivados de isoxazolidina